laitimes

Knowledge Expansion: How much do you know about autoimmune pancreatitis? | Summary of the article

author:Yimaitong Gastroenterology
Knowledge Expansion: How much do you know about autoimmune pancreatitis? | Summary of the article

Guide

Autoimmune pancreatitis (AIP) is a chronic, hormone-reactive inflammatory disease of pancreatic fiber, often clinically presenting as obstructive jaundice, with or without pancreatic parenchymal mass, histologically lymphoplasmic infiltrates and chronic fibrosis, and therapeutically showing a high sensitivity to hormonal drugs.

This article mainly reviews the diagnosis and treatment of AIP to help clinicians better understand the disease.

Typing and diagnosis of AIP: type 1 and type 2

The international consensus of AIP diagnostic criteria divides AIP into types 1 and 2 based on histopathological features.

Type 1: i.e., lymphoplastic sclerosing pancreatitis (LPSP), associated with serum immunoglobulin G4 (IgG4), usually with a characteristic elevation of serum IgG4 levels and other IgG4-related disorders. At present, Asian patients are mainly type 1, accounting for more than 96%.

Type 2: idiopathic ductal central pancreatitis (IDCP), associated with epithelial granulocyte damage, may be accompanied by ulcerative colitis. Type 2 AIP in Europe and the United States is not uncommon, showing a mixed prevalence of type 1 (80%).

The international standard describes the typical diagnostic characteristics of AIP from six aspects: pancreatic parenchymal imaging, main pancreatic duct imaging, serology and extrapancreatic lesions, histology, and hormone therapy response, and divides the evidence intensity into grades 1 and 2 according to evidence-based medicine, as the basis for the current clinical diagnostic work, see Table 1.

Table 1 Type 1 AIP International Diagnostic Standards

Knowledge Expansion: How much do you know about autoimmune pancreatitis? | Summary of the article

A diagram summary: The treatment of AIP

Treatment for AIP is shown in Figure 1, but close follow-up and monitoring of the likelihood of underlying malignancy is required.

Knowledge Expansion: How much do you know about autoimmune pancreatitis? | Summary of the article

Figure 1 Treatment of AIP

IgG4-SC, IgG4-associated sclerosing cholangitis; MMF, mycophenolate mofetil; 6-MP, 6-mercaptopurine; AZA, azathioprine

Knowledge Expansion: How much do you know about autoimmune pancreatitis? | Summary of the article

bibliography:

[1] Akshintala VS, Singh VK. Management of Autoimmune Pancreatitis[J]. Clin Gastroenterol Hepatol. 2019 Sep;17(10):1937-1939. doi: 10.1016/j.cgh.2019.04.052.

Sun Bei, Ji Liang. Interpretation of the Expert Consensus on the Treatment of Autoimmune Pancreatitis by the International Association of Pancreatology in 2016[J]. Chinese Journal of Practical Surgery, 2017,37(02):153-156.DOI:10.19538/j.cjps.issn1005-2208.2017.02.13.

Wang L W, Li J Ang, Rong Y F, et al. Progress in diagnosis and treatment of autoimmune pancreatitis[J]. Chinese Journal of Practical Surgery, 2020,40(06):741-744.DOI:10.19538/j.cjps.issn1005-2208.2020.06.25.